Home » Avacta’s AffiDX COVID-19 Antigen Self-Test Receives CE Mark
Avacta’s AffiDX COVID-19 Antigen Self-Test Receives CE Mark
Cambridge, UK-based Avacta Group has received a CE mark certification for its AffiDX SARS-CoV-2 rapid antigen self-test.
The company partnered with Medusa Healthcare to secure regulatory approval for the test, which Medusa will market under the brand name MeduFlow.
The AffiDX test, which delivers a result in 20 minutes, was clinically validated at the Carlos III hospital in Madrid, Spain, where it was shown to have a sensitivity across a broad range of viral loads of 98 percent and a specificity of 99 percent.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct